Work ongoing on election-delayed DAMA:
This article was originally published in Clinica
The German competent authority, BfArM, which oversees pharmaceutical product registration and materio- and pharmacovigilance, has been restructured in what is seen as the first phase of changes ahead of its eventual transformation into an agency, called DAMA. The new German pharmaceutical and medical products agency, whose passage into law has, however, been delayed by the SPD's early election call, will have a high level of autonomy and a modern management structure with which to set policy for the E23bn pharmaceutical and E20bn medical technology sectors, said temporary institute head Professor Reinhard Kurth. A law enacting DAMA will have to await the next legislative period.
You may also be interested in...
UK HTA body NICE is looking to the future and rethinking its approach to data and how they inform its guidance.
Slovenia’s Krka has responded to media reports of “irregularities” at its Romanian subsidiary – including allegations of bribing local doctors to prescribe its products – by pledging to form a special investigation team to immediately examine the matter.